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Male sexual dysfunction is common in chronic kidney disease (CKD), particularly in 
end-stage renal disease. Historically, this cause of considerable morbidity has been 
under-reported and under-recognized. The ideal approach to diagnosis and manage-
ment remains unclear due to a paucity of good quality data, but an understanding 
of the pathophysiology is necessary in order to address the burden of this important 
complication of CKD. This paper will review the endocrine dysfunction that occurs in 
renal disease, particularly the hypothalamic–pituitary–gonadal axis, discuss the causes 
of erectile dysfunction, infertility, and altered body image and libido in these patients and 
suggest appropriate treatment interventions.
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SeX HORMONe ABNORMALiTieS iN CHRONiC KiDNeY  
DiSeASe (CKD)
No organ system functions or fails in isolation. As CKD progresses, so the accumulating physiologi-
cal derangement disturbs the activities of other organs and tissues. With CKD, many components 
of the endocrine system are influenced. This is most evident in the extreme case, dialysis-treated 
end-stage renal disease (CKD stage 5-D). Disruption to the hypothalamic–pituitary–gonadal axis in 
men with CKD results in significant functional impairment and quality of life is affected.
A reduction in renal function may affect hormonal actions in a number of ways. Many hormones 
are metabolized or excreted by the kidneys. Sensitive feedback mechanisms are destabilized by 
CKD. Circulating binding proteins can alter in concentration, where there is renal dysfunction. 
Hyperprolactinemia and hypogonadism are two significant endocrine disturbances that occur in 
the setting of CKD.
Pituitary and Hypothalamic Alterations
In the normal state, pulsatile hypothalamic secretion of gonadotropin-releasing hormone (GnRH) 
stimulates the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by 
the pituitary gland. In turn, pituitary gonadotropin (LH and FSH) secretion is also pulsatile. LH is 
the prime regulator of testosterone production. FSH, in concert with high tissue testosterone levels, 
stimulates spermatogenesis.
In CKD, pituitary LH secretion maintains its pulsatile character, but the amplitude of the pulses is 
diminished (1–3). The baseline levels of LH are high, due in part to feedback from low testosterone 
levels and in part to reduced renal clearance. In addition to these secretory changes, the normal 
signaling of luteinizing hormone is inhibited in CKD (4). This appears to occur in a proportionate 
degree of severity to the reduction in glomerular filtration rate (GFR).
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The explanation for this aberrant gonadotropin secretion may 
lie within the hypothalamus or the pituitary. Defects in both 
hypothalamic function and pituitary gonadotropin release have 
been postulated, with some supporting evidence in CKD (3). The 
administration of clomiphene induces an appropriate increase in 
LH and FSH in men with CKD, suggesting that a hypothalamic 
derangement is “holding back” normal pulsatile GnRH secretion. 
Similarly, GnRH infusion augments LH production in subjects 
with CKD, as would be expected in normal individuals. However, 
the same blunted waveform of pulsatile LH secretion described 
above persists, which points to a pituitary problem. Despite this, 
the exact mechanisms for these endocrine abnormalities remain 
obscure.
Changes in Testosterone Production
Testosterone deficiency (or hypogonadism) is common in patients 
with CKD and particularly in those receiving dialysis. Published 
data suggest perhaps 40–60% of hemodialysis patients exhibit 
hypogonadism (5, 6), and a lower figure of around 15–40% applies 
to CKD stages 1–4 (7). This prevalence is notably in excess of the 
general population rate. Insufficient gonadotropin stimulation 
contributes to the etiology, but other factors are also significant. 
The production of testosterone naturally declines with age, and 
there is increased circulating sex hormone-binding globulin 
(SHBG) which in turn reduces free testosterone. The increasing 
age of the dialysis population means that the age-related fall in 
testosterone activity serves to exacerbate the effects of CKD.
Primary hypogonadism has been implicated by studies 
showing a blunted testosterone response to human chorionic 
gonadotropin stimulation (8, 9). Testicular size is reduced in 
CKD and histological abnormalities are identifiable, including 
seminiferous tubular derangement, interstitial fibrosis, and areas 
of calcification.
Serum testosterone levels have been shown to predict 
mortality in hemodialysis patients, although increasing age is a 
confounding variable and appears to account for much of the 
elevated mortality risk (6).
Changes in Prolactin Secretion
Prolactin is secreted principally by the anterior pituitary gland, 
with a contribution from peripheral tissues (10). Its function in 
women is to control breast development and lactation but in men 
its actions are less well understood. Hyperprolactinemia occurs 
commonly in CKD, with a prevalence of 30–65% (11–13). It is 
understood that this excess is due to a combination of diminished 
prolactin removal by the kidney and increased synthesis (14). The 
concept of renal clearance of prolactin in the physiologic state is 
not universally accepted, but a single and somewhat venerable 
study has shown a reduced metabolic clearance of prolactin in 
CKD stage 5-D (15), and an earlier publication reported a 16% 
reduction in prolactin concentration between renal artery and 
vein (12). The consequences of hyperprolactinemia are most 
marked in patients receiving dialysis therapy. The endocrine 
complications of hyperprolactinemia are manifest through 
disruption of pulsatile GnRH. This leads in turn to hypogonado-
tropic hypogonadism. The clinical features may include erectile 
dysfunction (ED), decreased libido, infertility, gynecomastia, and 
reduced skeletal mass (10, 16). It has been shown that elevated 
circulating prolactin levels are associated with cardiovascular 
events in men with ED (17). This has been reproduced in a study 
of CKD patients, incorporating two independent cohorts of 
hemodialysis and CKD stage 1 to CKD stage 5-ND subjects (14).
SHBG and Other Associated Hormonal 
Alterations
Sex hormone-binding globulin is the principal binding protein 
for testosterone in the circulation, with approximately 70% of the 
circulating hormone bound to it in normal circumstances. It is 
usual in men for SHBG levels to rise with advancing years, thus 
reducing available testosterone and exacerbating the age-related 
decline in testosterone production. In CKD, it appears that SHBG 
levels are unaffected by a decline in GFR. When adjusted for 
confounding factors, subjects with normal renal function or CKD 
stages 3–5-ND have similar measured SHBG (18). In a study 
of men with type 1 diabetes, progressive renal disease was not 
associated with SHBG alterations (19). It has been shown that a 
change from standard hemodialysis treatment for men with CKD 
stage 5-D to alternate nightly, longer sessions results in increased 
testosterone levels, while measured SHBG is unaffected (20). This 
suggests that greater delivery of dialysis improves testosterone 
bioavailability but not through SHBG effects.
Comorbidities in CKD Patients That Affect 
Sex Hormones
Those with CKD typically have relevant co-morbidities that result 
in hypogonadism, either by association with their kidney disease 
or as the cause of it. These include obesity, diabetes mellitus—
both type 1 and type 2, depression, and hypertension (21, 22). In 
particular, raised inflammatory biomarkers have been shown to 
be associated with low testosterone levels (23). Thus, a variety of 
inflammatory comorbidities are likely to be implicated, together 
with CKD per se in the development of hypogonadism.
Medications That influence Sex Hormone 
Abnormalities in CKD
Prescribed medications may interfere with testosterone pro-
duction. These include angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers (ARBs), spironolactone, 
and corticosteroids (24), which are often prescribed to patients 
with CKD. However, the case for ACE inhibitors and ARBs is 
controversial. While one study has argued that suppression of 
testosterone production is the link between ACE inhibitors and 
lower hemoglobin levels in hemodialyzed patients (25), another 
larger epidemiological investigation noted no apparent effect 
of ACE inhibitor/ARB use on serum testosterone levels in men 
receiving chronic hemodialysis (23).
In addition to these drugs, other agents sometimes used to 
treat men with CKD, which can exhibit antiandrogenic properties 
include cimetidine, ranitidine, and methotrexate.
eD iN CKD
Erectile dysfunction is defined as the persistent inability to 
achieve or maintain a penile erection sufficient for satisfactory 
TABLe 1 | Mechanisms of erectile dysfunction in chronic kidney disease.
Vascular Penile atherosclerotic disease
Endocrine Hypogonadism and hyperprolactinaemia
Neurologic Uremic and diabetic autonomic neuropathy
Pharmacologic Histamine antagonists, antihypertensives
Anemia Oxygen delivery to corpora cavernosa
Hyperparathyroidism Penile calcification and hyperprolactinaemia
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sexual activity. In CKD stage 5-D, the prevalence exceeds 80% 
(26). Although ED appears to become more common with 
declining GFR, the rate is high for all kidney disease from CKD 
stage 3 onward.
Mechanisms of eD
Multiple mechanisms for the development of ED in CKD have 
been studied. Table  1 outlines these, and they are discussed 
individually below.
Vascular
Chronic kidney disease is itself a risk factor for the development 
of atherosclerotic vascular disease. Even young patients receiv-
ing dialysis therapy have a cardiovascular mortality equivalent 
to octogenarians in the general population (27). Vascular dis-
ease has a close association with ED (28). This is unsurprising, 
given that the penile circulation is no less vulnerable than the 
remainder of the vascular tree to endothelial dysfunction and 
atherosclerosis. Impaired penile blood supply contributes to the 
development of ED.
Therefore, it might be expected that there will be a correlation 
between vascular disease and ED in CKD patients and that the 
excess of vascular disease in this population is partly responsible 
for the burden of ED. Indeed, an association has been shown 
between severe ED and coronary artery calcium score in dialysis 
patients (29) and between ED and carotid intima-media thick-
ness in hemodialysis recipients (30).
In a small study of 20 patients with CKD stage 5-D and ED, 
the combined use of pharmacocavernosography and pharmaco-
cavernosometry found evidence of cavernosal artery occlusive 
disease in 78% (31). This supports the contribution of penile 
atherosclerotic disease to ED in CKD.
Endocrine
As outlined above, the hypothalamic–pituitary–gonadal axis is 
disturbed in CKD. Hypogonadism is relatively common in this 
population and ED occurs in concert with the other physical 
consequences of testosterone deficiency.
Peripherally, testosterone affects the majority of pathways 
involved in normal erectile function, including smooth muscle 
cell structure, function, and innervation and maintains fibroe-
lasticity of the corpus callosum. There is a central effect of testos-
terone deficiency via reduction in sexual desire, which occupies 
an important role in ED. It is generally accepted that testosterone 
is required for the generation of nitric oxide via upregulation of 
neuronal nitric oxide synthase. This nitric oxide production is 
associated with the increased intracavernous pressure required 
for erectile function (32, 33).
In addition to its effects via hypogonadotropic hypogonadism, 
prolactin has been suggested to have a direct central effect on 
sexual arousal that contributes in a testosterone-independent 
manner to ED (34).
Neurologic
Adequate parasympathetic outflow is essential for cavernous sinu-
soidal relaxation and hence increased cavernosal blood flow. With 
autonomic neuropathy, the parasympathetic nervous system is 
impaired and this results in compromised erectile function (32). 
Diabetes mellitus is now the commonest cause of CKD stage 5-D. 
Autonomic neuropathy frequently accompanies type 1 diabetes 
mellitus when there is evidence of end-organ damage elsewhere. 
It is known that severity of cardiovascular autonomic neuropathy 
in patients with type 1 diabetes correlates with ED (35).
In addition to diabetes as a potential cause of autonomic 
neuropathy, it has been shown that uremia per se may result in 
autonomic nervous system dysfunction (36, 37). This neuropa-
thy appears irreversible; certainly, it is unresponsive to dialysis 
therapy. Significantly, there is a predilection for failure of the 
parasympathetic arm of the autonomic nervous system. A direct 
correlation between autonomic neuropathy in CKD and reduced 
nocturnal penile tumescence has been demonstrated (38). Thus, 
CKD-induced autonomic neuropathy, often abetted by diabetic 
autonomic neuropathy, constitutes an additional promoter of ED.
Pharmacologic
An extensive pharmacopeia is often found in the management 
of CKD. Hypertension is not universal, but the control of blood 
pressure remains the mainstay of therapy in many progressive 
kidney diseases despite therapeutic and diagnostic advances. In 
addition, hypertension is widespread in those patients requiring 
dialysis therapy, particularly in view of the chronic extracellular 
fluid volume expansion seen in this group. Antihypertensive 
agents comprise various drug classes, and some of those most 
frequently prescribed are associated with ED. The prescription of 
medications for other indications is common in CKD patients, 
and some of these too can be implicated in ED.
Of the antihypertensive drugs, diuretics, beta blockers, calcium-
channel blockers, and methyldopa are most strongly associated 
with ED. Other prescribed culprit medications include histamine 
antagonists and digoxin. Antidepressants present an interesting 
case. While depression is associated with ED and is a frequent 
comorbidity in CKD patients, treatment is not always associated 
with an improvement in ED (39). This might be explained by 
the known propensity of certain antidepressant medications to 
cause ED, particularly selective serotonin-reuptake inhibitors 
and tricyclic antidepressants. An alternative explanation might 
be that conventional antidepressant medication is lacking in 
efficacy generally in this patient group. It is recognized that there 
is very little good quality data in this area, but that patients with 
CKD stage 5-D have not been shown to derive much benefit from 
antidepressant drugs (40).
Anemia
Anemia is approximately twice as common in CKD as in the 
general population, and the prevalence rises in parallel with 
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falling GFR (41, 42). This surplus prevalence is accounted for 
by erythropoietin deficiency, which increases in likelihood and 
severity as kidney function declines. An association between 
anemia and ED has been reported in CKD (43). In anemia, there 
is a reduction in the delivery of oxygen to the tissues, and this 
includes the corpora cavernosa. Decreased oxygen availability is 
implicated in impaired nitric oxide generation within the erectile 
tissues and reduced erectile function (43, 44).
In current practice, patients with CKD stages 3–5 are treated 
with iron and erythropoiesis stimulating agents (ESAs) to 
maintain the hemoglobin within target parameters. This means 
that few such patients should be moderately or severely anemic. 
However, acknowledging an elevated risk of hypertension, stroke, 
and dialysis fistula thrombosis with increasing ESA dose, a typical 
target range for hemoglobin is between 10.0 and 11.5 g/dl (45). A 
consequence of this is that the majority of male CKD stage 4 and 
5 patients will be mildly anemic whether treated or not, compared 
to the normal range for healthy individuals. It is conceivable this 
will have an impact on ED, in conjunction with other risk factors.
Hyperparathyroidism
Varying degrees of secondary hyperparathyroidism, in some cases 
progressing to tertiary hyperparathyroidism, are near-ubiquitous 
in CKD stages 4–5. It has been suggested that hyperparathy-
roidism might contribute to the development of ED, whether 
independently or perhaps via prolactin release. Supporting 
evidence has come from the observation that penile calcification 
in a small group of hemodialysis patients correlated with ED (46). 
An observational study in which parathyroid hormone (PTH) 
was partially suppressed with calcitriol found an improvement 
in plasma testosterone levels and reported sexual function (47). 
Most intriguingly, a series of 20 hemodialysis patients in Taiwan 
that underwent subtotal parathyroidectomy for hyperparathy-
roidism was found to have improved sexual function 3 months 
postoperatively. This was associated with unaltered testosterone 
levels but a reduction in PTH and prolactin (48).
Relationship of eD to GFR
Given that CKD is a powerful risk factor for ED, it is intuitive 
that the severity of CKD will determine the degree of risk for 
the development of ED. Many of the etiological factors in 
CKD-associated ED will progress as GFR falls. These include 
hyperparathyroidism, hypogonadism, autonomic neuropathy, 
and vascular disease. Affirming this reasoning with data from 
the literature is more difficult due to heterogeneity in study 
populations, small sample sizes, and variation in study tools used 
to identify ED (49). An underpowered Brazilian study found a 
trend toward increasing prevalence of ED with advancing stages 
of CKD (50). In a series of non-dialyzed patients, rates of ED 
were 72.3% with CKD stage 3, 81.5% with CKD stage 4, and 
85.7% with CKD stage 5-ND. However, this apparent progres-
sion did not reach statistical significance. In a systematic review 
and meta-analysis of 50 studies, the overall rate of ED in CKD 
5-D patients was 75% with a lower rate of 59% in recipients of 
kidney transplants (CKD 5-T) (49). This might suggest that the 
restoration of GFR provided by the transplanted kidney results in 
improved erectile function.
A study examining the risk of ED following radical versus 
partial nephrectomy found a significantly higher rate of de novo 
ED in those subjected to radical surgery (51). This suggests that 
a greater reduction in nephron mass resulted in a greater risk of 
ED development.
Risk Factors for eD in CKD
Risk factors for any degree of ED in dialysis patients are numer-
ous, and perhaps a degree of caution needs to be exercised in 
their interpretation given the high prevalence of reported 
symptoms. Nevertheless, they include symptoms of depression, 
low educational attainment, diabetes, cardiovascular disease, 
hypertension as the stated cause of CKD, lower delivered dialysis 
dose, and alcohol abuse (39). Previous kidney transplantation 
and wait-listing for transplant appear to be protective. In a large 
meta-analysis of CKD patients with stage 4, 5-ND, 5-D, and 5-T 
disease, the strongest correlates for development of ED were 
diabetes (principally type 2 diabetes mellitus), depression, and 
increasing age (49).
Psychological Factors
Historically, ED was attributed primarily to psychological 
causes. In more recent times, the varied organic disorders that 
make up the majority of the burden of disease in ED have been 
given increasing prominence. Disentangling cause from effect 
where there is psychological morbidity and ED can be difficult. 
Nevertheless, psychological screening is essential in considering 
the etiology of ED.
Symptoms of depression have been strongly associated with 
the development of ED in patients with CKD (39), so too has 
unemployment. In CKD stage 5-D, depression may follow the loss 
of a primary role in occupation or the family or reflect reduced 
physical or cognitive function (52). In some dialysis patients, a 
sense of helplessness prevails, due to fears of complications or 
hospitalization.
Overall, 20–30% of dialysis patients have been shown to suf-
fer from clinical depression (53, 54). A study of CKD stage 4–5 
subjects with a GFR below 20 ml/min found that 25% had major 
depression and a further 20% had minor depression as measured 
by a structured interview questionnaire (55).
effect of Renal Transplantation on eD
It has been shown that renal transplantation can reverse the 
endocrine abnormalities associated with CKD stage 5 in the 
majority of allograft recipients. The restoration of kidney 
function, at least to a degree, improves prolactin clearance, 
and thus, LH and testosterone levels normalize (56, 57). 
Hyperparathyroidism and anemia also improve after successful 
transplantation. Vascular disease persists, however, although 
its progression might be retarded. A need for antihypertensive 
drugs or diuretics continues for some. Hence, a reduction in ED 
severity and prevalence might be expected posttransplant, but 
this will depend upon the predominant etiological mechanism. It 
is also worth observing that the majority of transplant recipients 
have spent time as dialysis patients and that their dialysis vintage 
is likely to influence erectile function after transplantation, as it 
does other outcomes.
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The published data supports this reasoning. ED is still widely 
prevalent in kidney transplant recipients, but not to the same 
degree as in CKD stage 5-D. If the prevalence of ED in dialysis 
patients is taken to be around 80% (26, 57), then epidemiological 
results suggest a lower level of approximately 30–50% following 
transplantation (57–59). Even allowing for the younger age and 
lower comorbidity of the transplanted population relative to 
dialyzed patients, this indicates that a sizeable proportion of men 
see improved erectile function following engraftment.
The availability of published data to compare erectile function 
pre- and post-transplantation is limited. A Chinese transplant 
center used the International Index of Erectile Function (IIEF) 
scoring system in 24 patients with CKD stage 5-D before and 
after a kidney transplant. In all, 87.5% experienced some degree 
of ED before surgery and 46% afterward (57). The majority of 15 
Iranian recipients of living donor organs reported better erectile 
function after kidney transplantation (60). Forty-seven percent 
had ED prior to surgery, perhaps a low figure. A higher rate of 
posttransplant ED was found in a larger cross-sectional study, 
reaching 55.7% of 271 recipients (59). Here, time on dialysis prior 
to transplantation was associated with negative effects upon erec-
tile function in the posttransplant period. Interestingly, a single 
small study examining ED after simultaneous kidney-pancreas 
(SKP) transplantation concluded that successful combined trans-
plantation restored near-normal levels of erectile function (61). 
Whether this simply reflects the lower age and dialysis vintage of 
the typical SKP recipient is unclear.
Quality of Life effects of eD in CKD
Unreported, unrecognized, or untreated ED has substantial 
implications for the sufferer. In a historical study of 17 married 
couples where one partner was treated with dialysis, marital 
discord and sexual dysfunction were closely linked (62). Quality 
of life, self-esteem, anxiety, and depression have been shown to 
be negatively influenced by ED in patients with CKD (63, 64). An 
inability to achieve satisfactory intercourse has adverse effects on 
quality of life in particular. According to one survey, the majority 
of peritoneal dialysis patients did not have intercourse, although 
50% of those surveyed would wish to (55). It is worth observ-
ing that quality of life and ED are associated in both directions: 
impaired quality of life due to kidney disease can worsen ED.
iMPACT OF CKD ON LiBiDO
Given the high prevalence of hypogonadism and ED in men 
with CKD, it is not unexpected that diminished libido is also a 
feature of the disease. One qualitative study using Diagnostic 
and Statistical Manual of Mental Disorders (DSM-III-R) criteria 
found that the majority (57–60%) of enrolled dialysis patients 
suffered “Hypoactive Sexual Desire Disorder” (65). This was 
compared to control groups with functioning kidney transplants 
or rheumatoid arthritis and no kidney disease, in whom the 
frequency was less than 13%, and the difference was statisti-
cally significant. It is established that libido is decreased in men 
with testosterone deficiency (66). Hypogonadism is likely to be 
an important factor in the reduced libido commonly seen in 
patients with CKD, particularly in CKD stage 5-D. In addition 
to the pathophysiological effects of endocrine dysfunction, CKD 
patients experience diminished quality of life due to impaired 
health (67), and this will also contribute to a reduction in libido. 
It has been shown that erythropoietin treatment of anemia in 
CKD results in improved libido, indicating an impact of low 
hemoglobin levels in reducing libido (68).
BODY iMAGe AND CKD
A significant proportion of adult CKD patients, particularly those 
with CKD stage 5, developed their kidney disease as children or 
adolescents. As a consequence, normal physical development is 
impaired despite ideal management. In addition to short stature, 
the body in patients with CKD stage 5-D or 5-T is altered both by 
the effects of kidney disease and the impact of treatment. There 
may be scars from vascular access procedures, peritoneal access 
surgery, or kidney transplantation. Hemodialysis or peritoneal 
dialysis catheters protrude from the skin, arteriovenous fistulae in 
the upper limbs are visible if the arms are exposed and the abdo-
men may distend from peritoneal dialyzate or enlarged polycystic 
organs. The eventual loss of native renal function and cessation of 
urine output also influence body image adversely.
Changing modality of renal replacement therapy from dialysis 
to kidney transplantation has an impact on body shape. Weight 
gain after kidney transplantation is common and can result in 
obesity in patients with a previously normal body mass index (69). 
Immunosuppressive medication prescribed after transplantation 
can also alter physical appearance, particularly where hirsutism 
develops with ciclosporin treatment (70).
A United Kingdom study of young adults aged 16–30 years 
with CKD stages 5-D and 5-T found that the impact of kidney 
disease and its treatment on body image had exerted a profound 
effect on intimate relationships (71). Using a bespoke, internally 
validated questionnaire, an Iranian study of 42 hemodialysis and 
42 kidney transplant patients found that both groups had altered 
body image, with a greater disturbance in the body image of the 
hemodialysis patients that reached statistical significance (72).
eFFeCT OF CKD ON MALe FeRTiLiTY
It is well established that men with CKD stage 5-D have sig-
nificantly lower fertility than members of the general population 
(56, 73, 74). In one small study of hemodialysis patients, more 
than 40% had oligospermia or azoospermia (56). This occurs 
due to deficiencies in sperm morphology, motility, and density 
(75). A recent Scandinavian study found a correlation between 
higher stages of CKD and declining semen quality (76). Testicular 
volume is reduced in dialysis patients in comparison to normal 
controls (77). The exact mechanism for impaired spermatogen-
esis remains unclear. The endocrine derangements described 
earlier go some way to accounting for abnormal sperm produc-
tion. The presence of oxidative stress has also been identified as a 
potential contributor to testicular dysfunction (77, 78). Oxidative 
stress is induced by various inflammatory pathways in CKD 
and exacerbated by the use of glucose-based peritoneal dialysis 
solutions or the extracorporeal circuit in hemodialysis. A single 
study has suggested that reduced expression of the cystic fibrosis 
TABLe 2 | Studies of phosphodiesterase-5 inhibitors in dialysis patients.
Study Design Population Drug Outcome
Türk et al. (91) Intervention; no control group 35 HD patients, 15 PD patients Sildenafil Significant improvement in International Index of 
Erectile Function (IIEF) score
Chen et al. (92) Intervention; no control group 34 HD patients, 1 PD patient Sildenafil Effective in 80% of patients (IIEF)
Yeniçeriog˘lu et al. (93) Intervention; no control group 30 HD patients, 11 PD patients Sildenafil IIEF score: 71% recovered erectile function
Seibel et al. (90) Double-blind, randomized, 
placebo-controlled
41 HD patients Sildenafil IIEF score: 85% improvement with sildenafil 
versus 9.5% placebo
Turk et al. (94) Randomized crossover 32 HD patients Sildenafil and 
Vardenafil
IIEF scores significantly improved by both drugs
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transmembrane conductance regulator by spermatozoa is associ-
ated with impaired sperm quality in uremia (79). However, the 
exact role of this protein in fertility is not established.
There are other contributory factors that may apply in a 
proportion of men with CKD. In patients with adult polycystic 
kidney disease, cyst development is not confined to the kidneys. 
Seminal vesicles can become cystic, and this may be an additional 
influence upon testicular function (80). Some patients with sys-
temic vasculitis, lupus nephritis, or primary glomerular disease 
are treated with cytotoxic medication such as chlorambucil or 
cyclophosphamide. These drugs possess gonadal toxicity (81), 
and if such patients progress to CKD stage 5-D, there will be an 
additional risk factor for infertility.
MANAGeMeNT OF SeXUAL 
DYSFUNCTiON iN CKD
erectile Dysfunction
A number of interventions have been proposed for the treatment 
of ED in CKD patients. However, a recent systematic review 
concluded that there is a lack of safety data for any therapeutic 
options for ED in this population (82). Small clinical trials con-
stitute the entirety of the evidence for efficacy even for the most 
comprehensively studied interventions. For most of the plausible 
treatment strategies, there is no published clinical trial data at all.
The initiation of dialysis therapy for patients with CKD stage 5 
improves some clinical characteristics but has not been shown to 
improve ED (83). The dialysis modality is probably unimportant. 
While the reported rate of ED in peritoneal dialysis patients 
might be lower (84), these patients are often younger than 
their hemodialyzed counterparts and have a lower comorbidity 
burden. Conversely, a number of studies have found that kidney 
transplantation has a beneficial effect upon sexual function in a 
significant proportion of patients previously treated with dialy-
sis. Longitudinal follow-up of hemodialysis patients who then 
received a kidney transplant has found a posttransplant improve-
ment in the IIEF score (57, 83, 85). Other small studies seeking 
to compare erectile function between groups of dialyzed and 
transplanted patients have come to similar conclusions, although 
this study design is less robust (86, 87).
The most comprehensively investigated treatment option for 
ED in CKD patients is the administration of phosphodiesterase-5 
inhibitors (PDE5i). PDE5i have been approved by the US FDA for 
treatment of ED since 1998. Three randomized controlled trials 
in CKD have compared PDE5i with placebo and demonstrated 
a consistent improvement in IIEF scores (88–90). Two of these 
studies recruited only kidney transplant recipients, the third 
investigated PDE5i in hemodialysis patients. The medications 
used were sildenafil in two trials and vardenafil in the other. In 
addition to this single randomized controlled trial of sildenafil 
in hemodialysis patients, three small uncontrolled studies and 
a randomized crossover trial of PDE5i have been published in 
dialysis (91–94). Table  2 summarizes the published data from 
dialysis patients including the single double-blind, randomized 
controlled trial. The intervention groups in all studies of PDE5i 
in transplanted or dialyzed subjects were small, ranging from 20 
to 39 patients (88–94). A recent Cochrane Review concluded 
that there was modest evidence for the efficacy of PDE5i in CKD, 
recognizing the paucity of well-designed randomized controlled 
trials and the small sample sizes (82).
A second therapeutic intervention that has attracted some 
attention historically is zinc supplementation. This has been 
studied as an oral supplement or as an additive to dialyzate in 
hemodialysis. Dialyzate zinc administration yielded no benefit 
in comparison to placebo when testosterone or gonadotropin 
levels were measured (95, 96). In contrast, a small double-blind, 
placebo-controlled trial of oral zinc in hemodialysis patients dem-
onstrated an improvement in endocrine parameters (increased 
testosterone, reduced LH) along with an increase in potency 
and frequency of intercourse in the zinc-treated subjects (97). It 
is worth noting that zinc studies are something of a historical 
artifact, with no major contribution to the literature in the last 
30 years.
Having recognized the significant prevalence of hyperpro-
lactinemia in the CKD stage 5-D population, bromocriptine 
has been investigated in the past as a treatment option in view 
of its ability to suppress prolactin levels. A small, uncontrolled 
interventional study found a normalization of prolactin levels in 
seven hemodialysis patients was associated with an improvement 
in self-reported sexual function and testosterone levels (98). Two 
slightly larger randomized crossover studies reported a high rate 
of intolerance of bromocriptine but a subjective improvement 
in ED when compared to placebo (99, 100). These accumulated 
data seem insufficient to endorse bromocriptine as a valuable 
intervention for ED in the CKD setting.
Testosterone replacement has also been considered as a 
means of addressing CKD-associated endocrine dysfunction 
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and subsequent ED. It has been observed that men suffer a more 
rapid progression of renal disease than women (101). Laboratory 
studies in animals suggest that testosterone might bear some 
responsibility for this, although corroborating clinical data in 
humans are lacking. Nevertheless, the use of testosterone supple-
mentation in patients with pre-dialysis CKD might be regarded 
with a degree of caution. This concern is of less relevance in 
established CKD stage 5-D. Setting this aside, there is also an 
understandable reluctance to prescribe testosterone replacement 
through anxiety that prostate cancer might be promoted. Such 
fears have not been comprehensively supported by the literature. 
No statistically elevated risk of prostate cancer was found in 
middle-aged and older men treated with testosterone replace-
ment (102). Notwithstanding this, prostate specific antigen 
(PSA) monitoring is recommended by the Endocrine Society for 
those men receiving testosterone therapy for androgen deficiency 
(103). Salt and water retention has been reported in hemodialysis 
patients treated with testosterone, and its use in CKD patients is 
considered a caution.
The recognition that low testosterone levels are associated with 
increased cardiovascular mortality has given further impetus to 
pharmacological testosterone replacement in patients with and 
without CKD. Unfortunately, it still remains unclear whether 
such replacement actually worsens cardiovascular and all-cause 
death in treated patients (104).
Despite these reasons for circumspection and insufficient data 
to assure long-term safety, a case can be made for the replenish-
ment of testosterone to physiological levels in androgen-deficient 
men (24, 103). Therefore, this will apply to a sizeable propor-
tion (40–60%) of CKD patients, as described above. Contra-
indications include the presence of prostate cancer or palpable 
prostatic nodules, PSA above 4 ng/ml, untreated severe obstruc-
tive sleep apnea, and prostatic hypertrophy causing severe lower 
urinary tract symptoms. Benefits of correcting hypogonadism 
might include improvements in ED, as evidenced by two small 
uncontrolled case series (105, 106), although a third study found 
little gain from treatment (107).
In cases where the administration of certain medications 
might be implicated in the development of ED in CKD patients, 
a careful review of treatment indications and alternative interven-
tions is warranted. A reappraisal of prescribed antihypertensive 
treatment can highlight drugs most likely to promote or induce 
ED. Thiazide diuretics and beta blockers in particular are strongly 
associated with ED (32). Alternative agents such as ACE inhibi-
tors or ARBs (despite their potential effects on testosterone) can 
be offered, and alpha blockers are usually less problematic in this 
situation. Histamine antagonists such as ranitidine are also likely 
culprit medications and might be exchanged with proton pump 
inhibitors. A history of high alcohol intake, while less common in 
patients receiving dialysis therapy, should prompt lifestyle advice 
and the offer of behavioral intervention.
Surgical treatment remains an option in CKD patients with 
sexual dysfunction. The only non-pharmacological therapy to 
have been investigated and published in this context is vacuum 
detumescence therapy, which showed promising results in a small 
cohort of 26 dialysis patients (108). It is generally considered 
that the use of penile prostheses is justifiable if pharmacological 
therapy has failed. In the dialysis patient, this might be deferred 
until after transplantation where reasonable, given the expecta-
tion that a significant proportion will regain erectile function 
posttransplant.
Acknowledging the connection between depression, quality 
of life and sexual dysfunction in CKD—particularly CKD stage 
5—other interventions might prove productive. Antidepressant 
pharmacotherapy has a limited and conflicting evidence base, 
but psychosocial intervention with cognitive behavioral therapy 
(CBT) has also been studied. A randomized crossover trial in New 
York recruited hemodialysis subjects and compared immediate 
CBT with a wait-listed group. The CBT was delivered chairside 
during dialysis sessions. Treated patients fared better than those 
as yet untreated in various domains including depression scores 
and quality of life (109). A randomized controlled trial of CBT 
versus no intervention in an Indian hemodialysis population 
found significantly improved anxiety and depression scores in 
the CBT group (110).
infertility
Specific treatment of male infertility in CKD is poorly studied, 
and there is a paucity of published work. It is recognized that 
successful kidney transplantation results in improved endocrine 
parameters and also higher semen quality. Sperm motility, mor-
phology, and number are increased, although this may take some 
time after engraftment of a functioning kidney (74, 108).
CONCLUSiON
The male endocrine system is substantially deranged with pro-
gressive CKD. A major consequence is a reduction in effective 
testosterone, which arises due to both primary and hypogonado-
trophic hypogonadism as well as altered SHBG levels. Although 
low testosterone is associated with both morbidity and mortality, 
the influence of increasing patient age is difficult to separate from 
direct effects of androgen deficiency. Testosterone replacement 
for androgen-deficient male CKD patients has some support 
from expert guidelines, but lacks a robust evidence base and 
carries theoretical risks.
In addition to endocrine dysfunction, the intimate relation-
ships of CKD patients are challenged by altered body image, 
diminished libido, and reduced fertility.
Management of ED in CKD centers upon the prescription of 
phosphodiesterase inhibitors. Pragmatic review of antihyperten-
sive therapy can help to minimize ED as a side effect of certain 
medications.
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